SupplementaryTable 2. Studies with infliximab administration in pediatric CD patients with fistula (IFX: infliximab, CD: Crohn’s disease) IFX schedule Fistula closure References Number of patients Side effects (5mg/kg) rate headache, fever, rash, eczema, neutropenia, muscle Ruemmele FM pain (n=10) n=40 et al. 2009 0, 2, 6 weeks Week 10, 9/13 (fistula: n=13) (147) delayed adverse effects (n=3) infection (n=15) Cezard JP n=21 0, 2, 6 anaphylactic reaction et al. 2003 Day 90, 12/12 (fistula: n=12) (n=1; single 1 inj.) (n=1) (151) Lionetti P n=22 Week 18, 7/13 Reinfusion based on dyspnea, rash, hypotension et al. 2003 (fistula: n=7) CD, 5/6) clinical condition (n=2 ) (152) (fistula + refractory CD: n=6) (late CD, 2/7) 3/16 de Ridder L 0, 2, 6 allergic reaction n=30 (6/16 et al. 2004 Reinfusion based on (n=6) (fistula: n=16) nonproductive (162) clinical condition death in sepsis (n=1) fistula)
References Number of patients IFX schedule (5mg/kg) Fistula closure rate Side effects Ruemmele FM et al. 2009 (147) n=40 (fistula: n=13) 0, 2, 6 weeks Week 10, 9/13 headache, fever, rash, eczema, neutropenia, muscle pain (n=10) delayed adverse effects (n=3) infection (n=15) Cezard JP et al. 2003 (151) n=21 (fistula: n=12) 0, 2, 6 (n=1; single 1 inj.) Day 90, 12/12 anaphylactic reaction (n=1) Lionetti P et al. 2003 (152) n=22 (fistula: n=7) (fistula + refractory CD: n=6) Reinfusion based on clinical condition Week 18, 7/13 CD, 5/6) (late CD, 2/7) dyspnea, rash, hypotension (n=2 ) de Ridder L et al. 2004 (162) n=30 (fistula: n=16) 0, 2, 6 Reinfusion based on clinical condition 3/16 (6/16 nonproductive fistula) allergic reaction (n=6) death in sepsis (n=1) SupplementaryTable 2. Studies with infliximab administration in pediatric CD patients with fistula (IFX: infliximab, CD: Crohn’s disease)
1-s2.0-S1873994614001482-mmc2.docx